37 results about "Tight junction" patented technology

The present invention provides a nutritional composition comprising one or more of vitamin D, polydextrose and galacto-oligosaccharides in combination with a calcium source. The composition has the effect of improving the intestinal mucosal barrier including improving intestinal mucosal permeability, modulating expression of intercellular tight junction proteins, improving intestinal mucosal tissue structure and improving levels of markers of the intestinal mucosal barrier.

The application discloses a human vagina micro-ecological in-vitro model and a construction method and application thereof, and relates to the technical field of medicines.The application discloses a human vagina micro-ecological in-vitro model and a construction method and application thereof.Firstly, a mixed cell group of the vaginal epithelium containing a complete cell lineage and capable of long-term subculture is successfully established, a technical bottleneck that primary vaginal epithelial cells are difficult to expand is solved, and ideal seed cells are provided for model construction.Secondly, a highly-bionic vaginal mucosa model having a tight connection structure, rich layers and an orderly arrangement is constructed, and the physiological barrier and immune regulation functions of the vaginal mucosa are truly simulated.Finally, by introducing lactobacillus symbiosis and confirming the response to estrogen, a multi-element in-vitro research model integrating the anatomical structure of the vagina, resident flora, local immunity and endocrine regulation is constructed, and a reliable technical platform is provided for in-depth exploration of the mechanism of vaginal micro-ecological disorder and efficient screening of related drugs.

The present application relates to the technical field of medicine, in particular to a kind of siRNA eye drop for penetrating mucus barrier and cell barrier and preparation method thereof.Innovative development side chain guanidino group-containing polydisulfide delivery carrier is used in the present application, through the quick dynamic disulfide exchange reaction between polydisulfide and sulfhydryl on mucin, tear film retention and efficient penetration are realized, and cationic polydisulfide is quickly adsorbed on the surface of negative charged cell membrane by electrostatic interaction, the quick dynamic disulfide exchange reaction between polydisulfide and sulfhydryl on cell membrane is used, and endocytosis is used to quickly penetrate tight junction cell layer.

The application discloses application of butyric acid in preparation of a medicine for treating oral ulcer, and belongs to the field of biological medicine. The butyric acid plays a therapeutic effect by increasing expression of tight junction proteins in oral mucosa tissue, reducing inflammatory reaction and promoting healing of oral ulcer. The application uses butyric acid to treat oral ulcer, evaluates the curative effect of butyric acid and explores the corresponding internal mechanism. The results show that the butyric acid has obvious effect in treating oral ulcer caused by chemotherapy, and provide a scientific basis for clinical application of butyric acid.

Present invention relates to a method of treating a disorder by administering an effective amount of a pharmaceutical composition comprising a therapeutic agent bound to a p80 neurotoxin associated polypeptide (NAP) derived from Clostridium Botulinum Type E (BoNT / E). The p80 is bound to a therapeutic agent, comprising one or more of: drugs, dyes, small molecules, biomolecules, proteins or a combination thereof. P80 enhances the transportation of the therapeutic agent into the bloodstream for increased bioavailability because thep80 is a tight junction modulator to enhance the permeability of the intestinal epithelium so as to facilitate drug delivery.

The invention provides a pharmaceutical composition for protecting intestinal injury caused by chemotherapy and application, and belongs to the field of medicines. The invention also provides a pharmaceutical composition for protecting intestinal mucosa tight junction injury caused by chemotherapy. The pharmaceutical composition is prepared from the following raw material medicines in parts by weight: 1-3 parts of astragalus polysaccharide and 1-3 parts of ziyuglycoside I. According to the invention, the compatibility of astragalus polysaccharide and ziyuglycoside I not only can improve the immunity of the organism after chemotherapy, but also can protect intestinal mucosal injury caused by intestinal chemotherapy drugs, and solves the problem that no special-effect drug for intestinal injury after chemotherapy exists in the current market, and pharmacodynamic tests prove that when the compatibility of astragalus polysaccharide and ziyuglycoside I is used, the curative effect is obvious. The intestinal mucosa tight junction injury caused by chemotherapy is protected, and the synergistic effect is achieved. The composition disclosed by the invention has the effects of protecting intestinal injury caused by pet chemotherapy or diarrhea of young animals, maintaining the integrity of the form and the structure of intestinal tissues, enhancing the immunity of the young animals, reducing the economic loss and reducing the use of antibiotics.

The application provides a pharmaceutical composition for protecting intestinal injury caused by chemotherapy and use, and belongs to the field of medicines. The application also provides a pharmaceutical composition for protecting tight junction injury of intestinal mucosa caused by chemotherapy, which is prepared from raw medicinal materials in the following proportions by weight: 1-3 parts of astragalus polysaccharide and 1-3 parts of sanguisorba officinalis saponin I. The astragalus polysaccharide combined with the sanguisorba officinalis saponin I can not only improve the immunity of the body after chemotherapy, but also protect the intestinal mucosa injury caused by intestinal chemotherapy drugs, and solves the problem that there is no specific drug for intestinal injury after chemotherapy on the market. The drug efficacy test proves that the astragalus polysaccharide combined with the sanguisorba officinalis saponin I has a synergistic effect on protecting the tight junction injury of intestinal mucosa caused by chemotherapy. The composition of the application can protect the intestinal injury of pets caused by chemotherapy or diarrhea of young animals, maintain the integrity of the intestinal tissue morphology and structure, enhance the immunity of young animals, reduce economic losses, and reduce the use of antibiotics.

This invention discloses a mixture of artemisia annua extract and rosemary extract and its application in the field of dermatology. The invention provides a mixture of artemisia annua extract and rosemary extract, a preparation method, and applications. This mixture can regulate the function of macrophages and epidermal cells, enhancing the phagocytic capacity of macrophages and initiating normal skin immune defense. Simultaneously, it can inhibit the overexpression of inflammatory factors, increase the expression of tight junction proteins in epidermal cells, and restore the skin barrier.

This invention relates to the fields of biomedicine and food nutrition, specifically to the application of purple sweet potato anthocyanins in the preparation of products for preventing or improving intestinal aging. This invention demonstrates that purple sweet potato anthocyanins can significantly improve the degenerative changes and barrier fragility of the colon caused by natural aging, restore colonic crypt morphology and epithelial ultrastructure, and upregulate the expression of tight junction proteins and mucus barrier-related indicators. Furthermore, purple sweet potato anthocyanins can effectively enhance crypt proliferation activity and promote the differentiation of intestinal stem cells into secretory lineages (such as goblet cells and enteroendocrine cells). Its mechanism of action does not rely on direct anti-inflammatory pathways, but rather on remodeling intestinal flora metabolism (such as increasing short-chain fatty acids) and activating intestinal cell autophagy via the PI3K-Akt signaling pathway, thereby supporting the continuous renewal and maintenance of the intestinal barrier. This invention provides a new approach for the development and application of food-derived polyphenols targeting the gut to promote healthy aging.

The method is for modulating tight junction (TJ) integrity in a subject. The method comprises (a) evaluating TJ integrity in a subject by quantifying at least one biomarker of TJ integrity in the subject; (b) administering the subject a first composition containing (i) at least one polyphenol and (ii) a second substance, rather than a polyphenol, that upregulates CAMP gene expression in the subject; (c) re-evaluating TJ integrity in the subject by quantifying at least one biomarker of TJ integrity in the subject; and (d) repeating steps (b) and (c) until the value of the at least one biomarker falls within the target range.

The application discloses a recombinant virus-like nanoparticle for immunotherapy of gastric cancer and application thereof. The recombinant virus-like nanoparticle is a chimeric recombinant virus-like nanoparticle formed by self-assembly of a fusion protein HBC-CLDN18.2 of a hepatitis B virus core protein and CLDN18.2 tight junction protein. The application uses genetic engineering technology to truncate the C-terminal end of a natural hepatitis B virus core antigen, and mutate cysteine residues at positions 48 and 107 into serine, so that the hepatitis B virus core antigen can self-assemble into a virus-like nanoparticle with strong stability. The virus-like nanoparticle is used as a carrier, a B cell epitope peptide (tight junction protein CLDN18.2) of a gastric cancer tumor-related antigen is inserted into an immunodominant site of the carrier, so that the humoral immune response against gastric cancer is enhanced. Two T cell epitope peptides of the heterologous hepatitis B virus core antigen are used to replace T cell epitope peptides on the carrier, so that the cellular immune response against gastric cancer is enhanced, and strong antitumor effect and immune memory effect are shown.

The application discloses application of ginseng glycoprotein monomer in preparation of a medicine for treating intestinal inflammation, and belongs to the technical field of biological medicine. The ginseng glycoprotein monomer extracted by the application has a molecular weight of 27kDa, a total sugar content of 65.3±2.0%, and a total protein content of 29.9±0.2%. The ginseng glycoprotein monomer can effectively treat Caco-2 cell activity reduction, cell monolayer integrity reduction and inflammatory factor release caused by DSS, and restore tight junction protein ZO-1 and Occludin expression. Therefore, the ginseng glycoprotein monomer can be used for preparing an effective medicine for treating intestinal inflammation.

The invention provides a plant lactobacillus MLPCO23 resistant to PEDV (porcine epidemic diarrhea virus) infection and application of the plant lactobacillus MLPCO23, and belongs to the technical field of microorganisms. The preservation number of the plant lactobacillus MLPCO23 is CCTCC (China Center for Type Culture Collection) NO: M 20252370. The plant lactobacillus MLPCO23 can be colonized in intestinal tracts, has a remarkable PEDV (porcine epidemic diarrhea virus) resisting effect, and can be used for improving the PEDV infection resisting capability of piglets and relieving clinical symptoms caused by PEDV infection. The plant lactobacillus MLPCO23 can repair intestinal villi and close connection structures, increase the number of goblet cells and maintain the steady state of intestinal barriers. The plant lactobacillus MLPCO23 serving as intestinal probiotics provides a new intervention target and a prevention and control strategy for PEDV infection, and also provides a new thought and a new clue for clarification of the effect and mechanism of Min pig flora for regulating intestinal mucosa microecology and resisting PEDV infection.

The application relates to an oral drug delivery system with a double-emulsion structure and application thereof in preparation of a medicine for treating premature ovarian insufficiency, and belongs to the technical field of biological medicines. The oral drug delivery system comprises an oil-phase solvent, MSCs conditioned medium is wrapped in the inside to form a droplet particle, and exosomes are uniformly distributed on the outer surface of the droplet particle, thereby forming a double-emulsion structure. The water-soluble MSC-CM is wrapped by a water-in-oil-in-water method to form a double-emulsion structure, so that the water-soluble protein is absorbed into the human body in an oral mode. The application has good structural stability and viscoelasticity, the particle size range is about 10-50 mu m, the contact with the intestinal epithelial cells is facilitated, meanwhile, the skeleton of the intestinal epithelial cells can be changed, the expression of the tight junction protein of the intestinal epithelial cells is lowered, the tight junction barrier of the intestinal epithelial cells is opened, and therefore the bioavailability of the MSC-CM is improved, and the role of treating POI is played.

The invention discloses a semen euryales gel with an intestinal barrier repairing function and a preparation method of the semen euryales gel, and belongs to the field of medical biological materials. The preparation method comprises the following steps: drying and crushing Asiaocai fruits, carrying out ultrasonic extraction to obtain an Asiaocai extracting solution, preparing a composite solution from the Asiaocai extracting solution and additives such as sodium alginate or modified sodium alginate, finally dropwise adding the composite solution into a coagulating bath containing a divalent or trivalent metal ion cross-linking agent, and carrying out a cross-linking reaction to obtain the Asiaocai gel. According to the gel, a compact and stable three-dimensional network structure is constructed through the combined action of the semen euryales pectin and the modified polysaccharide, the gel has excellent mechanical strength, gastrointestinal tract degradation resistance and precise colon targeting performance, the intestinal barrier can be repaired through the dual mechanisms of reconstructing epithelial cell tight connection and repairing a mucous layer, and the intestinal tract targeting effect is improved. The symptoms of weight loss, colon shortening and the like of mice with acute colitis are remarkably improved, inflammatory cell infiltration is reduced, an efficient targeted delivery carrier is provided for treating inflammatory bowel diseases, and the application prospect is wide.

The application provides application of Elaeagnus conferta polysaccharide in preparation of a medicine for treating intestinal barrier related diseases, and relates to the technical field of natural medicine chemistry. The intestinal protection effect of the Elaeagnus conferta polysaccharide on a dextran sodium sulfate induced intestinal injury model of mice is investigated, and the research result shows that the Elaeagnus conferta polysaccharide can treat clinical symptoms such as diarrhea, enteritis and weight loss caused by intestinal barrier injury, significantly reduces disease scores, inhibits colonic tissue goblet cell necrosis, promotes secretion of mucin, increases expression of tight junction proteins, and enhances intestinal mucosal barrier function. As a widely planted fruit and a fruit loved by the public, the Elaeagnus conferta has the advantages of high safety and easy acquisition. It is expected to become an effective active ingredient source for resisting intestinal injury diseases, and has a broad market development prospect.

The present application finds that ITIH4 secreted by macrophages can promote the viability and repair of intestinal epithelial cells, promote the expression of intestinal tight junction protein ZO-1, and inhibit the expression of macrophage inflammatory factors, and is an effective molecule for treating intestinal inflammation. Based on this, the present application provides the use of ITIH4 in the preparation of a medicament for treating intestinal inflammation.

The application discloses a kind of film type L-arginine-alpha-ketoglutarate salt sustained-release particles and its preparation method and application.The sustained-release particles include internal core material and external wall material, internal core material is L-arginine-alpha-ketoglutarate salt, external wall material is homogeneous complex matrix of stearic acid and sodium alginate, and the mass ratio of core material and wall material is 7:3 to 8:2.The sustained-release particles are obtained by stearic acid-sodium alginate complex wall material cold spray coating L-arginine-alpha-ketoglutarate salt, realize the synergistic effect of gastric acid tolerance and intestinal target release.Under 0.75%-1.00% additive dose, the sustained-release particles can significantly repair fish intestinal physical barrier, up-regulate tight junction protein and oligopeptide transporter expression, reduce serum intestinal permeability markers, and simultaneously activate muscle mTOR signaling pathway, promote collagen deposition, reduce drip loss rate, and comprehensively improve fish intestinal health and muscle quality.

It is found that ITIH4 secreted by macrophages can promote intestinal epithelial cell activity and repair, promote expression of intestinal tight junction protein ZO-1 and inhibit expression of macrophage inflammatory factors and is an effective molecule for treating intestinal inflammation. On the basis, the invention provides application of ITIH4 in preparation of a medicine for treating enteritis.

The invention discloses a boletus edulis extract as well as a preparation method and application thereof, and provides application of the boletus edulis extract in preparation of medicines, health-care products or functional foods for preventing and / or treating senile intestinal dysfunction caused by colonic atrophy and degeneration. The preparation method of the boletus edulis extract comprises the following steps: crushing boletus edulis, extracting with water or an alcohol solvent, filtering to obtain an extracting solution, concentrating the extracting solution, and drying to obtain the boletus edulis extract. The boletus edulis extract provided by the invention can up-regulate the expression of tight junction protein ZO-1 and mucoprotein MUC-2 in the colon of an aging body and promote the growth of colon length and crypt depth, thereby delaying the degeneration of colon atrophy and enhancing the digestive absorption and immune function of intestinal tracts.

Present invention relates to a method of making a recombinant p80 polypeptide using an E. coli culture comprising a plurality of E. coli host cells each transformed or transfected with an expression vector containing a DNA fragment encoding a recombinant p80 polypeptide; and inducing the E. coli culture by adding a 0.2% L-Arabinose. The isolated, recombinant p80 is added to a pharmaceutical composition, wherein it binds to a therapeutic agent comprising one or more of: drugs, dyes, small molecules, biomolecules, proteins or a combination thereof. The p80 polypeptide enhances the transportation of the therapeutic agent into the bloodstream by the p80 functioning as a tight junction modulator to enhance the permeability of the intestinal epithelium to the therapeutic agent.

The invention relates to the technical field of biotechnology and microbial screening, in particular to an organoid culture method for screening probiotics with an intestinal nutrition repairing function. The method comprises the following steps: firstly, culturing a human intestinal organ on a Transwell filter membrane to form polarized monolayer intestinal epithelium containing various functional cells; then co-culturing with probiotics to be detected or a product thereof in a lower chamber, and establishing a stable in-vitro interaction model; finally, comprehensively evaluating the intestinal nutrition repair function of the probiotics through an index system of five dimensions including transmembrane resistance measurement, tight junction protein analysis, short-chain fatty acid response, stem cell proliferation detection and nutrition transporter expression detection. The model has the advantages of being high in physiological correlation, good in standardization degree and comprehensive in evaluation dimension, the limitation that an existing screening model is simple in structure, single in function dimension and insufficient in physiological predictability is overcome, and the functional probiotic screening platform is high in physiological correlation, standardized and comprehensive in evaluation.

The application discloses a pig breed disease resistance breeding screening method based on taurine cholate metabolic markers, and belongs to the technical field of animal breeding. The application effectively screens the breeding pigs with stronger intestinal barrier function by establishing a breeding standard based on the intestinal barrier function difference, especially taking the taurine cholate level as a key index, and improves the health level and production benefit of pigs. Compared with the prior art, the ileum villus height to crypt depth ratio of the breeding pig is increased by 25.3%, the mRNA relative expression amount of ZO-1 and other tight junction proteins is increased by 32.7%, the SIgA and IgG levels are increased by 38.5%, the health level of the pig is significantly improved, and the production benefit is increased by 15.6%.

The present invention relates to a peptide for treating inflammation and wounds and, more specifically, to use of a peptide for treating inflammation and wounds, wherein the peptide binds to collagen type VII exposed by damage to tissue and recognizes collagen type VII as an antigen, thereby inhibiting the induction of an immune response, and thus having a function of inhibiting inflammation caused by an autoimmune response, and has the function of promoting wound healing by promoting cell proliferation and migration to a wound site in the damaged tissue. The peptide according to the present invention has the binding ability to collagen type VII, and thus inhibits an immune response caused by collagen type VII, thereby inhibiting inflammation caused by an autoimmune response. In addition, the peptide can bind to the integrin beta 1 of intestinal epithelial cells and increase the cell adhesion and migration via phosphor-FAK signal and tight junction markers are increased via FAK-RhoA signal and thus promote intestine regeneration.

The invention belongs to the field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating post-infection irritable bowel syndrome as well as a preparation method and application thereof. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 10 to 15 parts of rhizoma atractylodis macrocephalae, 10 to 20 parts of radix paeoniae alba, 3 to 7 parts of pericarpium citri reticulatae, 5 to 15 parts of radix saposhnikoviae, 10 to 20 parts of folium microcotis, 10 to 20 parts of plumeria rubra, 5 to 15 parts of kapok, 25 to 35 parts of rhizoma smilacis glabrae and 5 to 15 parts of flos albiziae. Animal experiments show that the traditional Chinese medicine composition can effectively improve diarrhea phenotypes and depressive symptoms of rats with PI-IBS liver depression and spleen deficiency syndromes, relieve high sensitivity of viscera, recover a tight junction structure and a cell desmosome structure of colon, up-regulate cell TJ protein expression, recover Th1 / Th2 immune imbalance of blood, reduce the level of proinflammatory factors (TNF-alpha) in colon tissue, and improve the immunity of the rats. And the levels of LPS, DAO and D-LA in serum are up-regulated. Therefore, the traditional Chinese medicine composition disclosed by the invention can be used for effectively treating the liver depression and spleen deficiency syndrome of the irritable bowel syndrome after infection.

The invention relates to an arrangement for attaching a tubular gas sampling probe (1) with at least one gas sampling inlet opening (2) arranged at the end of the tube to a channel wall defining a gas flow channel, the channel wall having a channel wall opening whose shape and size allow a section of the gas sampling probe (1) having the gas sampling inlet opening (2) to pass through.The arrangement comprises the following components: - the gas sampling probe (1), - a plate-shaped fastening element (13) that can be attached to the channel wall and has an opening which, when attached to the channel wall, completely overlaps the channel wall opening and has an internal thread, - a support tube (9) which has at its tube end a joining contour (11) with an external thread contoured to the internal thread for detachably tight joining to the opening of the plate-shaped fastening element (13), - a fastening element (10) attached to the support tube (9) for detachably fixing the gas sampling probe (1) inside the support tube (9), and - at least one line marking (8) attached to the gas sampling probe (1) as well as to the support tube (9) and / or to the plate-shaped fastening element (13).8'), which indicates at least an orthogonal distance to the channel wall between the gas sampling inlet opening (2) and the channel wall, as well as a relative rotational position between the gas sampling probe (1) and the support tube (9). The invention also relates to the use of this arrangement for air sampling in an air duct of a ventilation system.

In accordance with various aspects of the present disclosure, the disclosure relates to a method of treating cancer comprising (a) administering to a subject an anti-tight junction protein-1 antibody; (b) determining a PRO-C3 level in a test sample from the subject; and (c) comparing the level of PRO-C3 in the test sample to the level of PRO-C3 in a control sample. In some aspects, if the level of PRO-C3 in the test sample is not reduced relative to the level of PRO-C3 in the control sample, the dose of an anti-tight connexin-1 antibody administered to the subject is increased. In some aspects, if the level of PRO-C3 in the test sample is reduced relative to the control sample, the dose of an anti-tight connexin-1 antibody administered to the subject is not increased.

This invention discloses a targeted extracellular vesicle delivery system for the blood-brain barrier via the nasal-brain pathway, aiming to overcome the technical bottlenecks of existing technologies, such as low drug delivery efficiency to the brain, lack of targeted blood-brain barrier repair, and inability to achieve synergistic drug delivery and barrier repair. This system utilizes surface-modified exosomes of a special origin, encapsulating small-molecule drugs for treating neurodegenerative diseases. By bypassing the physiological blood-brain barrier through the nasal-brain pathway, the system directly enters the brain. It can accurately identify and accumulate adhesion molecule sites highly expressed in focally disordered areas of the blood-brain barrier, releasing the drug at the target site for focal targeted therapy. Simultaneously, it regulates tight junction protein expression to repair the disordered blood-brain barrier, achieving a synergistic effect of drug delivery and barrier regulation. This reduces toxic side effects in normal brain regions, breaks the vicious cycle of disease and barrier damage, exhibits excellent biocompatibility, is easily industrialized, and can effectively improve the treatment efficacy of neurodegenerative diseases.

The application discloses application of Bacteroides fragilis in preparation of products for preventing and / or treating celiac disease, and a composition containing Bacteroides fragilis for treating and / or preventing celiac disease. The application proves through a large number of experiments that Bacteroides fragilis, especially Bacteroides fragilis ZY-312 with a preservation number of CGMCC No. 10685, can increase the expression of tight junction related proteins, improve intestinal barrier permeability, down-regulate TTG-IgA antibodies and pro-inflammatory factors IFN gamma and IL-15, reduce inflammation, and effectively prevent and treat celiac disease.

Bifidobacterium bifidum CANM183 and extracellular vesicles thereof are applied to avoid intestinal injury and promote intestinal health. The application discloses application of Bifidobacterium bifidum CANM183 or extracellular vesicles thereof with a preservation number of CGMCC NO. 35416 in preparation of products for promoting intestinal health and avoiding intestinal injury. After oral delivery, the specific particle size extracellular vesicles derived from the strain can actively antagonize physical attacks caused by harmful pathogenic bacteria and harmful pathological vesicles secreted by the harmful pathogenic bacteria in a local microenvironment of the intestine, significantly improve a transmembrane resistance value of intestinal epithelial cells, and up-regulate continuous expression of a tight junction protein in situ to efficiently repair a damaged intestinal physical barrier. In addition, the natural antibacterial substances enriched in the extracellular vesicles can accurately inhibit abnormal proliferation of conditional pathogenic bacteria, reshape intestinal microecological genus level structure, and silence excessive expression of local pro-inflammatory cytokines in the colon, so that a new deep targeted intervention strategy and exact material basis are provided for improving microecological imbalance and avoiding intestinal pathological injury from the most upstream source of macromolecular penetration blocking.